Target 48 Neurodegeneration
Available now
Gain Clarity in Complexity: Transforming Neurodegeneration Research with Biomarker Precision


Olink® Reveal
Product
Powerful, NGS-based proteomics - effortlessly uncover meaningful insights

Olink Insight
Journey from experiment planning and study design to post-run data analysis – in a single online bioinformatic app.
Landmark articles in Nature show the power of population-scale proteogenomics
Publications
Read the latest impressive findings from the UK Biobank Pharma Proteomics Project.


Empowering genomics with high-throughput proteomics
E-book
Explore recent advancements in our pioneering field. Discover how top scientists use high-throughput proteomics to advance precision medicine.
One platform. Endless possibilities.
PEA Technology
Meet the next-generation proteomics platform trusted by small lab teams and leading pharma companies.
Latest news
Stay updated with the latest Olink news, including press releases, events, and notable publications describing cutting-edge research and key advancements in proteomics.
Blog
UK Biobank Population-level Studies Using Olink’s PEA Technology Advance Disease Understanding and Therapy Development
Explore the transformative potential of integrating proteomics with genomics. Dr. Ryan Dhindsa’s research with UK Biobank data using Olink’s PEA technology identifies thousands of rare genotype-protein associations, revealing new disease-associated genes and therapeutic targets.
Press release
Thermo Fisher Scientific Expands Neurodegeneration Research Capabilities with Launch of Olink® Target 48 Neurodegeneration Panel
Today, we announced the launch of the Olink® Target 48 Neurodegeneration Panel – a high-performance, targeted proteomics immunoassay panel designed to accelerate discoveries in neurodegenerative disease research.
